Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Cheng Website

Sheue-yann Cheng, Ph.D.

Selected Publications

1)  Furuya F, Hanover JA, Cheng SY.
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
Proc. Natl. Acad. Sci. U.S.A. 103: 1780-5, 2006.
[Journal]
2)  Fozzatti L, Lu C, Kim DW, Park JW, Astapova I, Gavrilova O, Willingham MC, Hollenberg AN, Cheng SY.
Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1).
Proc. Natl. Acad. Sci. U.S.A. 108: 17462-7, 2011.
[Journal]
3)  Kim WG, Guigon CJ, Fozzatti L, Park JW, Lu C, Willingham MC, Cheng SY.
SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.
Clin. Cancer Res. 18: 1281-90, 2012.
[Journal]
4)  Fozzatti L, Kim DW, Park JW, Willingham MC, Hollenberg AN, Cheng S.
Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor a.
Proc. Natl. Acad. Sci. U.S.A. 110: 7850-7855, 2013.
[Journal]
5)  Kim DW, Park JW, Willingham MC, Cheng SY.
A histone deacetylase inhibitor improves hypothyroidism caused by a TRa1 mutant.
Hum. Mol. Genet. 23: 2651-64, 2014.
[Journal]
6)  Kim WG, Zhao L, Kim DW, Willingham MC, Cheng SY.
Inhibition of tumorigenesis by the thyroid hormone receptor ß in xenograft models.
Thyroid. 24: 260-9, 2014.
[Journal]
7)  Wark L, Danescu A, Natarajan S, Zhu X, Cheng SY, Hombach-Klonisch S, Mai S, Klonisch T.
Three-dimensional telomere dynamics in follicular thyroid cancer.
Thyroid. 24: 296-304, 2014.
[Journal]
8)  Duncan Bassett JH, Boyde A, Zikmund T, Evans H, Croucher PI, Zhu X, Won Park J, Cheng SY, Williams GR.
Thyroid hormone receptor a mutation causes a severe and thyroxine-resistant skeletal dysplasia in female mice.
Endocrinology. en20132156, 2014.
[Journal]
9)  Ward Y, Lake R, Martin PL, Killian K, Salerno P, Wang T, Meltzer P, Merino M, Cheng SY, Santoro M, Garcia-Rostan G, Kelly K.
CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model.
Oncogene. 32: 2726-38, 2013.
[Journal]
10)  Kim DW, Walker RL, Meltzer PS, Cheng SY.
Complex temporal changes in TGFß oncogenic signaling drive thyroid carcinogenesis in a mouse model.
Carcinogenesis. 34: 2389-400, 2013.
[Journal]
11)  Kim WG, Park JW, Willingham MC, Cheng SY.
Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model.
Endocrinology. 154: 2936-47, 2013.
[Journal]
12)  Park JW, Zhao L, Cheng SY.
Inhibition of estrogen-dependent tumorigenesis by the thyroid hormone receptor ß in xenograft models.
Am J Cancer Res. 3: 302-11, 2013.
[Journal]
13)  Fozzatti L, Park JW, Zhao L, Willingham MC, Cheng SY.
Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer.
PLoS ONE. 8: e67954, 2013.
[Journal]
14)  Kim WG, Zhu X, Kim DW, Zhang L, Kebebew E, Cheng SY.
Reactivation of the silenced thyroid hormone receptor ß gene expression delays thyroid tumor progression.
Endocrinology. 154: 25-35, 2013.
[Journal]
15)  Kim WG, Cheng SY.
Thyroid hormone receptors and cancer.
Biochim. Biophys. Acta. 1830: 3928-36, 2013.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 6/20/2014.